APA 6th Edition Milunović, V., Bogeljić Patekar, M., Mandac Rogulj, I., Planinc-Peraica, A. i Ostojić Kolonić, S. (2016). SUVREMENI PRISTUP NE-HODGKINOVU LIMFOMU PLAŠTENE ZONE: PREGLED LITERATURE. Liječnički vjesnik, 138 (11-12), 0-0. Preuzeto s https://hrcak.srce.hr/173555
MLA 8th Edition Milunović, Vibor, et al. "SUVREMENI PRISTUP NE-HODGKINOVU LIMFOMU PLAŠTENE ZONE: PREGLED LITERATURE." Liječnički vjesnik, vol. 138, br. 11-12, 2016, str. 0-0. https://hrcak.srce.hr/173555. Citirano 27.01.2020.
Chicago 17th Edition Milunović, Vibor, Martina Bogeljić Patekar, Inga Mandac Rogulj, Ana Planinc-Peraica i Slobodanka Ostojić Kolonić. "SUVREMENI PRISTUP NE-HODGKINOVU LIMFOMU PLAŠTENE ZONE: PREGLED LITERATURE." Liječnički vjesnik 138, br. 11-12 (2016): 0-0. https://hrcak.srce.hr/173555
Harvard Milunović, V., et al. (2016). 'SUVREMENI PRISTUP NE-HODGKINOVU LIMFOMU PLAŠTENE ZONE: PREGLED LITERATURE', Liječnički vjesnik, 138(11-12), str. 0-0. Preuzeto s: https://hrcak.srce.hr/173555 (Datum pristupa: 27.01.2020.)
Vancouver Milunović V, Bogeljić Patekar M, Mandac Rogulj I, Planinc-Peraica A, Ostojić Kolonić S. SUVREMENI PRISTUP NE-HODGKINOVU LIMFOMU PLAŠTENE ZONE: PREGLED LITERATURE. Liječnički vjesnik [Internet]. 2016 [pristupljeno 27.01.2020.];138(11-12):0-0. Dostupno na: https://hrcak.srce.hr/173555
IEEE V. Milunović, M. Bogeljić Patekar, I. Mandac Rogulj, A. Planinc-Peraica i S. Ostojić Kolonić, "SUVREMENI PRISTUP NE-HODGKINOVU LIMFOMU PLAŠTENE ZONE: PREGLED LITERATURE", Liječnički vjesnik, vol.138, br. 11-12, str. 0-0, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/173555. [Citirano: 27.01.2020.]
Sažetak Mantle cell lymphoma (MCL) represents the fourth most common type of non-Hodgkin lymphomas. It is characterized by aggressive course and frequent relapses. The main aim of this review is to evaluate current treatment approach towards this type of lymphoma. In younger patients the chemotherapy including high doses of cytarabine is the gold standard. In case of complete or partial remission, the consolidation with autologous stem cell transplantation is indicated as consolidation approach. In older patients CHOP-R regimen is not the treatment of choice. These patients should be treated with bendamustine in combination with rituximab. In case of complete or partial remission, further therapy with rituximab maintenance as consolidation represents an option. The vast majority of patients with MCL will ultimately relapse which poses a challenge in treatment approach. The approach in relapsed MCL can be divided in two types: chemotherapy or biologic therapy. In young fit patients chemotherapy based on bendamustine and cytarabine is a reasonable option. In patients with comorbidities or poor performance status biologic agents are reasonable options. Ibrutinib, Bruton kinase inhibitor, is characterized by highest overall response rate and the longest duration of response and should be offered to these patients. With the development of novel potent inhibitor of B cell receptor signaling pathway, these agents may become the gold standard in future and introduce the treatment of MCL in „chemo-free“era.